Directory
Serafin Morales Murillo

Serafin Morales Murillo

Degree: PhD

973 70 53 03
smorales.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/L-7216-2019

Groups

Publications

  • Alberola, V; Camps, C; Provencio, M; Isla, D; Rosell, R; Vadell, C; Bover, I; Ruiz-Casado, A; Azagra, P; Jimenez, U; Gonzalez-Larriba, JL; Diz, P; Cardenal, F; Artal, A; Carrato, A; Morales, S; Sanchez, JJ; de las Penas, R; Felip, E; Lopez-Vivanco, G

    Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish lung cancer group phase III randomized trial

    Journal of Clinical Oncology 21 3207-3213. .

    [doi:10.1200/JCO.2003.12.038]

  • Espinosa, E; Zamora, P; Milla, A; Morales, S; Molina, R; Mira, M; Baron, MG; Oncopaz Cooperative Grp

    A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 24 1054-1059. .

    [doi:10.1002/hed.10172]

  • Morales, S; Salud, A; Balil, A; Mira, M; Garcia, E; Carceller, JA

    Paclitaxel (P), gemcitabine (G) and cisplatin (c) in non-resectable non-small cell lung cancer (NSCLC).

    ANNALS OF ONCOLOGY 11 527-527. .

  • Morales, S; Garcia, E

    Phase III study of treatment with association of chemotherapy plus radiotherapy with or without sensibilisation with taxol in non small cell lung cancer in stage III

    EUROPEAN JOURNAL OF CANCER 35 70-70. .

  • Morales, S; Balil, A; Salud, A

    Second-line treatment with Topotecan in ovarian cancer

    EUROPEAN JOURNAL OF CANCER 35 87-87. .

  • BELLMUNT, J; ALBANELL, J; Salud, A; ESPANOL, T; Morales, S; SOLECALVO, LA

    INTERFERON aND DISSEMINaTED LaNGERHaNS CELL HISTIOCYTOSIS

    Medical And Pediatric Oncology 20 336-337. .

    [doi:10.1002/mpo.2950200413]

  • ALBANELL, J; Salud, A; BELLMUNT, J; ESPANOL, T; Morales, S; GARCIABRAGADO, F; SOLECALVO, LA

    TREaTMENT WITH INTERFERON OF aN aDULT SYSTEMIC LaNGERHaNS CELL HISTIOCYTOSIS

    MEDICINA CLINICA 94 184-186. .

  • Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F

    Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).

    BREAST 54 286-292. .

    [doi:10.1016/j.breast.2020.11.005]

Projects

  • Development of Computer Application (Apps) for Information and Monitoring of Patients with Breast Cancer at the Hospital Arnau de Vilanova De Lleida
  • SELECCIÓN DE TRATAMIENTO CON QUIMIOTERAPIA NEOADYUVANTE EN PACIENTES CON CÁNCER DE MAMA EN ESTADIO PRECOZ Y CON RECEPTORES HORMONALES POSITIVOS MEDIANTE LA DETERMINACIÓN DE LA PLATAFORMA ONCOTYPE, CF DNA EN SANGRE PERIFÉRICA Y CAMBIOS DEL MARCADOR KI67 EN TEJIDO TUMORAL.
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante